TY  - GEN
AU  - Garcia-Manero,Guillermo
AU  - Roboz,Gail
AU  - Walsh,Katherine
AU  - Kantarjian,Hagop
AU  - Ritchie,Ellen
AU  - Kropf,Patricia
AU  - O'Connell,Casey
AU  - Tibes,Raoul
AU  - Lunin,Scott
AU  - Rosenblat,Todd
AU  - Yee,Karen
AU  - Stock,Wendy
AU  - Griffiths,Elizabeth
AU  - Mace,Joseph
AU  - Podoltsev,Nikolai
AU  - Berdeja,Jesus
AU  - Jabbour,Elias
AU  - Issa,Jean-Pierre J
AU  - Hao,Yong
AU  - Keer,Harold N
AU  - Azab,Mohammad
AU  - Savona,Michael R
TI  - Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
SN  - 2352-3026
PY  - 2019///1030
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - adverse effects
KW  - Azacitidine
KW  - Dose-Response Relationship, Drug
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Myelodysplastic Syndromes
KW  - drug therapy
KW  - Neutropenia
KW  - etiology
KW  - Severity of Illness Index
KW  - Survival Rate
KW  - Thrombocytopenia
KW  - Treatment Outcome
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1016/S2352-3026(19)30029-8
ER  -